A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2002
11/13/2002	CN1379664A Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitor
11/13/2002	CN1379109A Adenovirus carrier for specifically killing primary liver cancer cells and its application
11/13/2002	CN1379082A Solid culture method of antrodia camphorate, its cultured solid substance, and its product and application
11/13/2002	CN1379047A Match of organic medicine and beta-cyclodextrin derivative and its preparing process
11/13/2002	CN1379041A Cytotoxin T lymphocyte
11/13/2002	CN1378859A Antalgic medicine for cancerous pain and its preparing process
11/13/2002	CN1378857A Oral liquid as Chinese medicine for treating esophagus cancer and its preparing process
11/13/2002	CN1378856A Chinese medicine for treating gynopathy
11/13/2002	CN1094152C 光合细菌的应用及利用它制得的产品 Application of photosynthetic bacteria and use it to obtain the product
11/13/2002	CN1094058C Chinese medicine preparation for treating leukemia and reversing drug-resistance
11/13/2002	CN1094054C Oral liquor for curing tumour disease
11/13/2002	CN1094052C Anticancer goose blood preparation
11/12/2002	US6479692 Reacting a keto-carboxy derivative with a substituted aniline to form an amide and treating to form an acylanilide
11/12/2002	US6479679 Two-step conversion of protected taxane ester to paclitaxel
11/12/2002	US6479678 Metal alkoxide taxane and β-lactam compounds
11/12/2002	US6479662 Antitumor dibenzofluorene derivatives
11/12/2002	US6479633 Chemokine alpha 2
11/12/2002	US6479630 Human purinergic P2U receptor
11/12/2002	US6479544 Therapeutic combinations of fatty acids
11/12/2002	US6479539 Procyanidin compositions and methods for making the same
11/12/2002	US6479531 Gastrin and cholecystokinin receptor ligands
11/12/2002	US6479517 Treatment of post-menopausal syndrome: osteoporosis, cardiovascular effects such as hyperlipidemia, and estrogen-dependent cancer, particularly breast and uterine cancer
11/12/2002	US6479513 Anticancer compound and enantiomer separation method useful for synthesizing said compound
11/12/2002	US6479512 Tyrosine kinase inhibitors
11/12/2002	US6479502 Hydroxamic acid derivatives as proteinase inhibitors
11/12/2002	US6479500 Alleviating side effects caused by use of an anti-tumor agent comprising administering 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1h,3h)-pyrimidin edione
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479487 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
11/12/2002	US6479481 Administering an effective dose of a cns tumor-inhibiting methylol transfer agent such as: taurolidine, taurultam or a mixture thereof.
11/12/2002	US6479471 Novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit n-acetylated .alpha.-linked acidic dipeptidase (naaladase) enzyme activity to treat prostate diseases
11/12/2002	US6479457 Polypeptide comprising at least one effective ionogenic amine ionically bound to polymer; drug delivery systems for the controlled release of pharmaceutical polypeptides
11/12/2002	US6479270 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
11/12/2002	US6479266 IKK-α proteins nucleic acids and methods
11/12/2002	US6479250 Eck receptor ligands
11/12/2002	US6479067 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/12/2002	US6479032 Calcitonin receptor binding reagents
11/12/2002	CA2244253C Method for preventing and treating peripheral neuropathy by administering selegiline
11/12/2002	CA2204535C Molecules that home to a selected organ or tissue in vivo and methods of identifying same
11/12/2002	CA2176738C Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
11/12/2002	CA2101227C Chlorophyll and bacteriochlorophyll derivatives and pharmaceutical compositions containing them
11/12/2002	CA2092435C Uracil reductase inactivators
11/12/2002	CA2088917C Therapeutic ribozyme compositions
11/12/2002	CA2079581C Crystalline etoposide 4'-phosphate diethanolate
11/11/2002	CA2385692A1 Thiazole derivatives
11/09/2002	CA2385744A1 Decalactones, method for making, and pharmaceuticals therefrom
11/07/2002	WO2002088714A2 Individualization of therapy with antineoplastic agents
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088358A2 Human fibroblast growth factor-related compositions
11/07/2002	WO2002088356A1 Novel g protein-coupled receptor protein and dna thereof
11/07/2002	WO2002088336A2 Genetically modified yt cell line and use thereof
11/07/2002	WO2002088334A1 Chimeric immunoreceptor useful in treating human cancers
11/07/2002	WO2002088328A2 Method for generating highly active human dendritic cells from monocytes
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088186A1 Anti-cd40 monoclonal antibody
11/07/2002	WO2002088182A1 Nove g protein-coupled receptor protein and dna thereof
11/07/2002	WO2002088172A2 Pentapeptide compounds and uses related thereto
11/07/2002	WO2002088170A2 Cripto blocking antibodies and uses thereof
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088138A1 Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
11/07/2002	WO2002088137A1 Pkb-3564 substance with neovascularization inhibitory activity
11/07/2002	WO2002088118A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	WO2002088115A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
11/07/2002	WO2002088112A1 Heterocyclic compound and antitumor agent containing the same as active ingredient
11/07/2002	WO2002088110A1 Quinoline derivative having azolyl group and quinazoline derivative
11/07/2002	WO2002088107A1 Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
11/07/2002	WO2002088106A2 Cysteine protease inhibitors
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088094A1 2-iminoimidazole derivatives (1)
11/07/2002	WO2002088092A1 2-iminoimidazole derivative (2)
11/07/2002	WO2002088090A2 Pyrazole derived kinase inhibitors
11/07/2002	WO2002088081A2 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088070A1 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
11/07/2002	WO2002087625A1 Composite oncolytic herpes virus vectors
11/07/2002	WO2002087619A1 Preventive/therapeutic method for cancer
11/07/2002	WO2002087618A1 Preventive/therapeutic method for cancer
11/07/2002	WO2002087617A1 Supplementary immunotherapeutics to be used after lung cancer removal
11/07/2002	WO2002087616A1 Preventives for postoperative recurrence of premenopausal breast cancer
11/07/2002	WO2002087612A2 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases
11/07/2002	WO2002087607A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
11/07/2002	WO2002087603A1 Immunopotentiators
11/07/2002	WO2002087600A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
11/07/2002	WO2002087593A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method
11/07/2002	WO2002087587A2 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
11/07/2002	WO2002087586A1 Sustained release drug delivery system containing codrugs
11/07/2002	WO2002087585A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	WO2002087583A2 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	WO2002087581A1 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
11/07/2002	WO2002087575A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002	WO2002087574A2 Use of pyridoindolone derivatives for preparing anticancer medicines
11/07/2002	WO2002087555A2 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/07/2002	WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	WO2002087509A2 Colloidal metal compositions and methods
11/07/2002	WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	WO2002087505A2 3-structure of a whole integrin $g(a)v$g(b)3 extracellular region and uses therefor
11/07/2002	WO2002087504A2 Methods for inhibiting tumor cell proliferation
11/07/2002	WO2002087497A2 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use

1 ... 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 ... 2211